12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alequel: Phase IIb data

In a double-blind Phase IIb trial in 43 patients, Alequel met the primary endpoint of remission rate (CDAI score <=150) at 2 consecutive time points 3 weeks apart. Between weeks 6-9, 43% patients receiving...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >